A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Public ClinicalTrials.gov record NCT07038369. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT07038369
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Atavistik Bio, Inc
- Industry
- Enrollment
- 134 participants
Conditions and interventions
Conditions
- Advanced Solid Tumors
- Breast Cancer
- Breast Carcinoma
- Breast Neoplasms
- ER Positive Breast Cancer
- Cervical Cancers
- Cervical Neoplasms
- Cervical Carcinoma
- Triple Negative Breast Cancer
- Gynecologic Cancers
- Gynecologic Neoplasm
- Endometrial Cancer
- Endometrial Neoplasm
- Endometrial Carcinoma (EC)
- Fallopian Cancer
- Ovarian Carcinoma
- Ovarian Cancer
- Ovarian Neoplasms
- Prostate Cancers
- Prostate Carcinoma
- Solid Tumors
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Uterine Neoplasms
- Genital Neoplasms, Female
- Urogenital Neoplasms
Interventions
- ATV-1601 Drug
- ATV-1601 + Fulvestrant Combination Product
Drug · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 28, 2025
- Primary completion
- Aug 30, 2028
- Completion
- Jan 30, 2029
- Last update posted
- Jun 2, 2026
2025 – 2029
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Florida Cancer Specialists & Research Institute - Lake Mary | Lake Mary | Florida | 32746 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07038369, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07038369 live on ClinicalTrials.gov.